Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab withdrawal versus continued treatment in non-radiographic axial spondyloarthritis
NL-OMON47719Phase 4Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of golimumab in non-radiographic axial spondyloarthritis (nr-axSpA) (3 arms), sponsored by Merck & Co. Primary endpoints: Primary efficacy endpoint and Flare definition. Started Oct 2017; status: recruiting.
02
Drugs
golimumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NL-OMON47719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47719.